1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Diabetic Neuropathy Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of diabetic neuropathy and the need for effective treatment methods
5.1.1.2. Increasing awareness pertaining to diagnosis & treatment of diabetes
5.1.1.3. Government initiatives for the management of diabetic neuropathy
5.1.2. Restraints
5.1.2.1. High failure rate in clinical trials and high cost of diabetic neuropathy treatment
5.1.3. Opportunities
5.1.3.1. Widening diabetic neuropathy research areas
5.1.3.2. Development of advanced drug delivery systems
5.1.4. Challenges
5.1.4.1. Complications associated with diabetic neuropathy treatment
5.2. Market Segmentation Analysis
5.2.1. Treatment Type: Wide use of drugs for pharmacological treatment in diabetic neuropathy for alleviating pain and stabilizing nerve function
5.2.2. Disorder Type: Preference for diabetic neuropathy due to increasing prevalence of peripheral neuropathy
5.2.3. Distribution channel: Emergence of online pharmacies as a convenient distribution channel for medications prescribed for diabetic neuropathy management
5.3. Market Trend Analysis
5.3.1. Ongoing research for the development of novel treatments and rise in approvals for diabetic neuropathy management systems in the Americas
5.3.2. Increasing prevalence of diabetes and emerging start-ups focused on developing diabetic neuropathy treatments and devices in the APAC region
5.3.3. Supportive government initiatives to improve diabetes disease treatment and care in the EMEA region
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
6. Diabetic Neuropathy Market, by Treatment Type
6.1. Introduction
6.2. Drugs
6.3.1. Analgesics
6.3.2.1. Non-Steroidal Anti-Inflammatory Drugs
6.3.2.2. Opioids
6.3.2.3. Topical
6.3.2. Anticonvulsants
6.3.3.1. Gabapentin
6.3.3.2. Pregabalin
6.3.3.3. Topiramate
6.3.3. Antidepressant
6.3.4.1. Serotonin & Norepinephrine Reuptake Inhibitors
6.3.4.2. SSRIs
6.3.4.3. TCAs
6.3. Physiotherapy
7. Diabetic Neuropathy Market, by Disorder Type
7.1. Introduction
7.2. Autonomic Neuropathy
7.3. Focal Neuropathy
7.4. Peripheral Neuropathy
7.5. Proximal Neuropathy
8. Diabetic Neuropathy Market, by Distribution channel
8.1. Introduction
8.2. Clinics
8.3. Hospitals
8.4. Online Pharmacy
8.5. Retail Pharmacy
9. Americas Diabetic Neuropathy Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Diabetic Neuropathy Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Diabetic Neuropathy Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
12.3.1. Merger & Acquisition
12.3.1.1. Tandem Diabetes Care completed acquisition of insulin pump maker AMF Medical
12.3.1.2. Withings acquired Devicemaker Impeto Medical
12.3.2. Agreement, Collaboration, & Partnership
12.3.2.1. Praetego awarded USD 300,000 by National Eye Institute to advance novel oral drug for diabetic retinopathy
12.3.2.2. P&G Health, IDF partnered to address Peripheral Neuropathy in people with diabetes
12.3.2.3. The RMH partnered with Australian Centre for Accelerating Diabetes Innovations
12.3.3. New Product Launch & Enhancement
12.3.3.1. Neuralace Medical Completes Enrollment of Painful Diabetic Neuropathy Label Expansion Study (AT-PDN) Paving the Way for FDA Clearance and a Breakthrough, Non-invasive Treatment for Diabetes related Neuropathic Pain
12.3.3.2. Abbott, Medtronic, and Nevro are developing SCS therapies to treat peripheral neuropathy treatment
a diabetic for diabetic
12.3.3.3. NeuroMetrix launched peripheral neuropathy test DPNCheck 2.0
12.3.3.4. Glenmark Pharma launched drug for diabetic patients with comorbidities
12.3.3.5. FDA Clears PENS Device for pain related to diabetic peripheral neuropathy
12.3.4. Investment & Funding
12.3.4.1. GBP 1.4 million Awarded to Create early test for Diabetic Peripheral Neuropathy
12.3.4.2. Regenacy Pharmaceuticals announced the completion of enrollment for phase 2 Study in diabetic peripheral neuropathy & USD 9.3 million series B financing
12.3.4.3. Medtech startup Yostra Labs raised Rs 4Cr in a Seed round to help patients suffering from chronic disease
12.3.5. Award, Recognition, & Expansion
12.3.5.1. Horizon Therapeutics PLC announced FDA approval of an update to the indication language for TEPEZZA (teprotumumab-trbw) to specify its use in thyroid eye disease (TED) patients regardless of disease activity or duration
12.3.5.2. FDA cleared Medtronic’s neurostimulator for diabetic peripheral neuropathy pain
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Abbott Laboratories
13.1.2. AdventHealth
13.1.3. Alkem Labs
13.1.4. Astellas Pharma Inc.
13.1.5. AstraZeneca PLC
13.1.6. Bauerfeind AG
13.1.7. Bayer AG
13.1.8. Boehringer Ingelheim International GmbH
13.1.9. Boston Scientific Corporation
13.1.10. Collegium Pharmaceutical, Inc.
13.1.11. Daiichi Sankyo Company, Limited
13.1.12. Dr. Reddy’s Laboratories Ltd.
13.1.13. Eli Lilly and Company
13.1.14. Glenmark Pharmaceuticals Limited
13.1.15. Grünenthal GmbH
13.1.16. Harmonium Pharma s.r.l.
13.1.17. Lupin Limited
13.1.18. Medtronic PLC
13.1.19. Merck KGaA
13.1.20. NeuroMetrix, Inc.
13.1.21. Nevro Corp.
13.1.22. Novartis AG
13.1.23. Novo Nordisk A/S
13.1.24. Pfizer Inc.
13.1.25. Praetego, LLC
13.1.26. Regenacy Pharmaceuticals, Inc.
13.1.27. Sanofi S.A.
13.1.28. Stem Cell Care India
13.1.29. Teva Pharmaceutical Industries Ltd.
13.1.30. The Procter & Gamble Company
13.1.31. Trevena, Inc.
13.1.32. Vertex Pharmaceuticals Incorporated
13.1.33. Viatris Inc.
13.1.34. Winsantor, Inc.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
